Latest News for: pd l1

Edit

PD-1 and PD-L1 Inhibitors Market: Trends, Growth, and Future Prospects

Pharmiweb 20 Mar 2025
Programmed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the body's immune response ... When PD-L1 binds to PD-1, it suppresses T-cell activity, preventing immune attacks.
Edit

The Global Cancer Biomarkers Market to Upsurge at a Tremendous CAGR of ~14% by 2030, ...

GetNews 19 Mar 2025
... integration of its AI-based PD-L1 scoring algorithm into Guardant's testing workflow to improve biomarker detection in the Guardant360 TissueNextTM PD-L1 test for non-small cell lung cancer (NSCLC).
Edit

The Study Showing the mRNA Vaccine Cancer Link That They Don’t Want You to See

The Daily Sceptic 19 Mar 2025
Add another to the pile ... mRNA Covid vaccines and cancer ... The study ... Source ... Source ... Studies show that mRNA Covid vaccines can suppress cancer immunosurveillance due to impacts on type I interferon (IFN) responses, BRCA2, PD-L1, p53 and IgG4 ... Source ... (2021).
Edit

Shilpa Biologicals Pvt Ltd signs strategic development partnership with mAbTree Biologics AG for a novel immuno-oncology asset

Pharmiweb 18 Mar 2025
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation and generation of strong immune responses against tumours akin ...
Edit

Releasing the Brakes: The Role of Immune Checkpoint Inhibitors in Cancer Therapy

The Scientist 13 Mar 2025
It binds to the APC-expressed ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) ... indicates that host cells within the TME and lymph nodes—such as APCs, fibroblasts, and T cells—also upregulate PD-L1 expression.
Edit

Rocket Companies (NYSE: RKT) to Acquire Redfin (NASDAQ: RDFN) in $1.75B Deal – More Stocks ...

GetNews 11 Mar 2025
Rocket Companies (NYSE ... (TSXV ... The acquisition brings UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma (cSCC), under Sun Pharma’s global onco-derm franchise.
Edit

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for ...

Business Wire 10 Mar 2025
A) today announced its PD-L1 IHC 28-8 pharmDx kit ... PD-L1 IHC 28-8 pharmDx is approved for exclusiv .
Edit

Sun Pharma to Acquire Checkpoint Therapeutics

Victoria Advocate 10 Mar 2025
Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for ....
Edit

Sun Pharma to acquire US oncology compony for over Rs 3,000 crore

The Times of India 10 Mar 2025
... an FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma’s global presence means patients may soon have access to an important, new treatment option.
Edit

Sun Pharma to acquire US oncology firm for over Rs 3000 crore

The Times of India 10 Mar 2025
Dilip Shanghvi, CMD of Sun Pharma, said, “Combining UNLOXCYT, an FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma’s global presence means patients may ...
Edit

Addressing Disparities in Liver Cancer Care

The Call 08 Mar 2025
Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to increased risk of immune-related rejection of the developing fetus, resulting in fetal deathVerify pregnancy ...
×